Email Updates

You are here

AVAC in the News

  • Zimbabwe will start its first HIV vaccine clinical trial as soon as regulatory approvals are achieved. The trial, named HVTN 107, will enroll 24 Zimbabwean participants (of a planned total 132 participants) to test a vaccine similar to the one that reduced risk of HIV infection by 31 percent in the RV144 trial in Thailand. HVTN 107 will also run in South Africa and Mozambique. An overview of AIDS vaccine research can be found here.

    August 30, 2015
    Zim Daily
  • New York City, which has one of the country’s highest rates of new HIV infections, has been quietly cutting many of the prevention services needed to fight the epidemic, according to many AIDS advocates.

    August 27, 2015
    BuzzFeed
  • Fred Schaich of IFARA speaks with Mitchell Warren, executive director of AVAC, about HIV prevention research presented at IAS 2015.

    August 24, 2015
    The Body Pro
  • After strongly advocating against PrEP, the AIDS Healthcare Foundation's new national ad campaign includes eleven principles on how to include PrEP as part of an HIV prevention strategy.

    August 19, 2015
    HIVPlusMag
  • The AIDS Healthcare Foundation, which has long waged a vociferous battle against Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), has finally begun to offer measured support for the HIV prevention method.

    August 18, 2015
    AIDSMEDS
  • 2013 and 2014 Global Lube Access Mobilization (GLAM) grants were awarded to partners in Africa to support their efforts advocating lubricant availability and educating gay men, men who have sex with men and transgender individuals about its proper use.

    August 13, 2015
    The Body
  • According to Nobel laureate Françoise Barré-Sinoussi, AIDS research has made immense progress over the last decades, but there's still a lot to be done. She says less attention is being paid to HIV in wealthy countries.

    August 4, 2015
    DW
  • Over the past decade, the US President’s Emergency Plan for AIDS Relief — in partnership with other countries and financing mechanisms — has helped change the trajectory of the AIDS epidemic. Yet, right now, PEPFAR is operating without targets. Read why targets are necessary and how they drive action.

    August 3, 2015
    Devex
  • The new National HIV/AIDS Strategy (NHAS), now updated for 2015-2020, is focused heavily on prevention and includes a strong endorsement of PrEP as a strategic option. This article in BuzzFeed takes on six common misconceptions about PrEP and clarifies what the science really has to say about this blue pill.

    August 2, 2015
    BuzzFeed
  • In the past, there was a sense that stopping the HIV/AIDS epidemic would require some radically new biomedical intervention. The growing consensus, however, is that the tools needed to stamp out HIV already exist if they could just be used in the right way.

    July 7, 2015
    Nature

Pages